Investigational drug · Phase 2
HM15275
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obese, Obesity, Type 2 Diabetes Mellitus.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "HM15275"
First trial start
2025
Dec 2, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HM15275", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obese
- Obesity
- Type 2 Diabetes Mellitus
- T2DM
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "HM15275" as an intervention, largest first.
- Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes MellitusPivotal-lookingActive, not recruiting
Hanmi Pharmaceutical Company LimitedIndustry
NCT07205900 · 267 participants · Start Dec 2, 2025 · Primary completion Jan 2027
Drug: HM15275; Placebo of HM15275 · For: Obese; Obesity
Sites: Chula Vista, California; Oak Lawn, Illinois; Ames, Iowa · 14 sites in all
- Study to Evaluate HM15275 in Subjects With Type 2 Diabetes MellitusPivotal-lookingRecruiting
Hanmi Pharmaceutical Company LimitedIndustry
NCT07527650 · 180 participants (planned) · Start May 18, 2026 · Primary completion Oct 2027
Drug: HM15275; Placebo of HM15275 · For: Type 2 Diabetes Mellitus; T2DM
Sites: Mesa, Arizona; Santa Clarita, California; DeLand, Florida · 20 sites in all
Hanmi Pharmaceutical Company LimitedIndustry
NCT06481098 · 74 participants · Start May 28, 2024 · Primary completion May 2, 2025
Drug: HM15275; Placebo of HM15275 · For: Obesity
Sites: Chula Vista, California
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Obese
- AleniglipronPhase 36 trials
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · Obesity, Overweight, Chronic Weight Management
- AcmopatideCT-868, RO7795074Phase 21 trial
Carmot Therapeutics, Inc. · Overweight, Obese, Type 1 Diabetes Mellitus
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.